Together, these findings constitute a consistent body of evidence supporting the viewthat drugs acting at the GRPR should be further evaluated as potential cognitiveenhancers to treat memory disorders associated with AD and other neurodegenerativeand psychiatric disorders. This evidence concerns the gene GRPR and psychiatric disorder.